This bill amends the Controlled Substance, Drug, Device and Cosmetic Act to include new provisions regarding the scheduling and secure storage of certain controlled substances, specifically medetomidine and xylazine. It adds medetomidine to Schedule III of controlled substances, defining it as a substance with a potential for abuse that is less than those in Schedules I and II, and outlines specific conditions under which it is not considered a controlled substance when used for nonhuman species or in pharmaceutical compounding by licensed professionals.

Additionally, the bill mandates that veterinarians comply with secure storage requirements for both medetomidine and xylazine, aligning with existing regulations under the Pharmacy Act. The changes aim to clarify the legal status of medetomidine in veterinary medicine and ensure proper handling and storage of these substances to prevent misuse. The act is set to take effect immediately upon passage.

Statutes/Laws affected:
Printer's No. 1082 (Jul 24, 2025): P.L.233, No.64